Kornimate/medical-research-clean huggingface dataset:
factors affecting outcome of vestibular rehabilitation

Conditions: Chronic Dizziness; Vestibular Disease

Summary: this is an observational longitudinal study to investigate if negative illness perceptions predict less improvement in dizziness handicap following vestibular rehabilitation. consecutive patients (n=260) who enter the vestibular rehabilitation programme at guy's hospital, london will be included. questionnaires will be conducted immediately before, and after their final treatment. the main outcome will be the dizziness handicap inventory after rehabilitation.

the aim of this longitudinal study is to investigate whether illness perceptions predict dizziness handicap following a treatment as usual 8-week vestibular rehabilitation programme in patients with chronic vertigo and dizziness. participants will be recruited consecutively from patients attending the dizziness and balance exercise programme at guys \& st thomas' nhs foundation trust. consenting patients will complete the following questionnaires before and after rehabilitation: 1. the dizziness handicap inventory (dhi) 2. the illness perceptions questionnaire - revised (ipq-r) 3. the patient health questionnaire anxiety and depression scale (phq-ads) the dizziness handicap inventory (dhi) at discharge will be the dependent variable. we will also demographic data including age, gender, and illness type.

Eligibility criteria:
inclusion criteria: * are aged above 18 years old and are enrolled onto the vestibular rehabilitation programme due to chronic dizziness exclusion criteria: * patients will be excluded if they have evidence of central nervous system disorders or cannot speak english.
pilot study of internet-delivered psychological treatment for cancer survivors

Conditions: Cancer Survivors; Anxiety; Depression

Summary: negative psychological effects of cancer are common, but cancer survivors are rarely offered structured psychological treatment. internet-delivered treatments have shown some promise, but specific treatment components have not been empirically evaluated which means that it is not clear which therapies that should be prioritized. in this factorial pilot study, 48 cancer survivors with psychiatric symptoms are enrolled in variations on a 10-week therapist-guided online psychological treatment intended to address common negative psychological long-term effects of cancer. the aim of this study is to assess the feasibility of the study design and online treatment format. key feasibility outcomes include interest in the study, patient-reported credibility of the intervention, adherence to the treatment protocol, satisfaction with the treatment, acceptability of the measurement strategy, missing data rates, adverse events, and preliminary efficacy on anxiety, depression, the fear of recurrence, and health-related quality of life.


Eligibility criteria:
inclusion criteria: * cancer survivor at least 0.5 years after main therapy. survivor of breast cancer (n=24), testicular cancer (n=12), or thyroid cancer (n=12). * clinically significant anxiety or depression (patient health questionnaire 9 \[phq-9\]≥10, or generalized anxiety disorder 7 \[gad-7\]≥8, or 9-item fear of cancer recurrence inventory \[fcri-9\]≥16) * at least 18 years old * resident of sweden (listed and de facto) * sufficient technical knowledge and knowledge of the swedish language to take part in a text-based online treatment * continuous access to an electronic device that can be used to access the study web platform exclusion criteria: * recurrent thoughts of suicide, as based on clinical judgement aided by the structured interview and the self-report version of the montgomery-åsberg depression rating scale (madrs-s) item 9 * severe medical condition (e.g., very poor prognosis, stage iv cancer), severe psychiatric disorder (e.g., psychotic disorder, bipolar disorder, or severely debilitating substance use disorder, severe depression), or medical treatment (e.g., chemotherapy, immunotherapy, radiotherapy) that makes the treatment unfeasible * other ongoing psychological treatment * continuous psychotropic medication not stable for the past 4 weeks, or not expected to remain stable during the treatment period * planned absence for more than one week of the intended treatment period * no complete the pre-treatment assessment

Keywords: psycho-oncology randomized factorial trial internet-delivered cognitive behavior therapy
cdss-assisted ugi endoscopy vs. routine screening endoscopy

Conditions: Healthy Individual

Summary: this study aimed to find the cdss-assisted upper gi endoscopy has clinical benefit compared to conventional routine screening upper gi endoscopy. investigators will conduct a pilot randomized controlled study. consecutive patients will be allocated either to cdss-assisted upper gi endoscopy or conventional routine screening upper gi endoscopy. the lesion detection rate will be compared between both groups.

artificial intelligence has been adopted in the field of gastrointestinal endoscopy. investigators previously established deep-learning models to predict the histology and invasion depth of gastric lesions using endoscopic stillcut images. however, clinical benefit of this model has not been evaluated. this study aimed to find the cdss-assisted upper gi endoscopy has clinical benefit compared to conventional routine screening upper gi endoscopy. investigators will conduct a pilot randomized controlled study. consecutive patients who visited chuncheon sacred heart hospital will be allocated either to cdss-assisted upper gi endoscopy or conventional routine screening upper gi endoscopy. the lesion detection rate will be compared between both groups. expert endoscopists will conduct this randomized study.

Eligibility criteria:
inclusion criteria: * participants who visited for routine screening upper gastrointestinal endoscopy exclusion criteria: * participants who refuse to participate in this study * participants who showed paradoxical reaction prohibiting routine examination

Keywords: convolutional neural network deep learning endoscopy gastric neoplasms
bioimpedance spectroscopy for the evaluation of heart failure

Conditions: Heart Failure

Summary: despite impressive improvements in treatment strategies, heart failure (hf) morbidity and mortality remains substantially high worldwide. pulmonary congestion is considered the leading cause for hospital admissions and death among patients with hf. physical examination is crucial for titrating medical treatment in these patients, but despite a good specificity it is not sensitive enough to detect early elevated cardiac filling pressures. the n-terminal pro-b-type natriuretic peptide (nt-probnp) is a recognized powerful predictor for hf prognosis. recently, cardiotrophin-1 and galectin-3 have been proposed as new relevant biomarkers for hf evaluation. echocardiography can be also used to noninvasively measure left ventricular filling pressures. lung ultrasound (lus) through interstitial b-line evaluation has been recently proposed as a bed-side, noninvasive tool to assess interstitial lung water. b-lines correlate with nt-probnp and e/e' levels in patients with acute dyspnea, chronic hf or after a stress test. lus can also identify clinically silent pulmonary edema, suggesting that it may complement clinical evaluation to improve hemodynamic profiling and treatment optimization. biompedance is a bedside method for total body fluid status assessment. it defines individual fluid status/compartments/overload on the basis of an individual's normal extracellular volume and body composition. recent studies indicate that bioimpedance-derived fluid overload indices are independent predictors of mortality in renal failure patients. to date, no study has evaluated bioimpedance performance for fluid assessment in hf patients. the investigators aim to cross-sectionally compare bioimpedance parameters with clinical evaluation, lus, cardiac biomarkers, and echocardiographic characteristics, in a cohort of incident consecutive patients with hf. two years patients' survival will be evaluated to propose the best evaluative algorithm and rank the various methods for prognostic significance.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years; 2. hf diagnosis regardless of cause as defined by the framingham criteria and satisfying the european society of cardiology guidelines; exclusion criteria: 1. metallic joint prostheses, cardiac stent or pacemakers, decompensated cirrhosis, pregnancy and limb amputations (due to bioimpedance technique limitations); 2. no prior diagnosis of pulmonary fibrosis (due to lung ultrasonography limitations); 3. absence of congenital heart disease

Keywords: heart failure bioimpedance lung ultrasonography
evaluation of sonelokimab for the treatment of patients with active moderate to severe hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: this is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.


Eligibility criteria:
inclusion criteria: 1. participant is ≥18 years of age; 2. participant has been diagnosed with hidradenitis suppurativa as determined by the investigator and has a history of signs and symptoms of hidradenitis suppurativa dating back at least 6 months prior to the screening visit; 3. participant has a total abscess and/or inflammatory nodule (an) count of ≥5; 4. participant has hidradenitis suppurativa lesions present in ≥2 distinct anatomical areas, at least one of which must contain single or multiple fistulas (i.e., be hurley stage ii or iii); 5. participant had an inadequate response to appropriate systemic antibiotics for treatment of hidradenitis suppurativa (or demonstrated intolerance to, or had a contraindication to, systemic antibiotics for treatment of their hs), in the investigator's opinion; 6. participant must be, in the opinion of the investigator, at both the screening visit and study treatment initiation, a suitable candidate for treatment with adalimumab per approved local product information. exclusion criteria: 1. participants with known hypersensitivity to sonelokimab or any of its excipients; 2. participants with known hypersensitivity to adalimumab or any of its excipients; 3. participant has a draining fistula count of ≥20 at the screening visit; 4. participant has any other active skin disease or condition that may, in the opinion of the investigator, interfere with the assessment of hidradenitis suppurativa; 5. prior exposure to more than 2 biologic response modifiers; 6. participant has a diagnosis of ulcerative colitis or crohn's disease.

Keywords: hidradenitis suppurativa hidradenitis sweat gland diseases skin diseases skin diseases, bacterial suppuration adalimumab anti-inflammatory agents sonelokimab nanobody folliculitis apocrine gland disease acne inversa
the efficacy and safety of pegylated gh for the treatment of short stature in chinese children-globe reg

Conditions: Growth Hormone Treatment; Growth Disorders

Summary: in order to further observe the long-term safety and effectiveness of real-world polyethylene glycol-recombinant human growth hormone(peg-rhgh) treatment of ghd, idiopathic short stature, and sga in children, explore and analyze the factors affecting the efficacy of peg-rhgh and the height prediction model after treatment, etc., collect and analyze more scientifically and rationally, and understand the situation of real-world peg-gh treatment. a database registration study was developed.

a database registration study was developed to retrospectively analyze the efficacy and safety of polyethylene glycol recombinant human growth hormone injection in the treatment of slow growth in children caused by endogenous growth hormone deficiency, idiopathic short stature, turner syndrome, etc., and to further prospectively follow up and monitor. in order to participate in the global real-world use of long-acting growth hormone, all data from this study were uploaded to the global registry of new therapies for rare endocrine diseases and bone disorders (globe-reg) platform.

Eligibility criteria:
inclusion criteria: patients with endogenous growth hormone deficiency, turner syndrome, sga, idiopathic short stature, etc. treated with polyethylene glycol recombinant human growth hormone injection exclusion criteria: patients with serious heart and lung, blood system, malignant tumors and other diseases or systemic infections, immune function is low and persons with mental illness;
evaluation of a novel human milk fortifier in preterm infants

Conditions: Preterm Infants

Summary: the purpose of this study is to assess growth of preterm infants fed human milk supplemented with an experimental human milk fortifier.


Eligibility criteria:
inclusion criteria: * 700-1500g birth weight * 33 weeks or less gestational age * appropriate for gestational age * initiate enteral feeds of human milk by 21 days of life * mother provided exclusive human milk feeds * parents allow both human milk and study human milk fortifier * singleton or twin birth exclusion criteria: * feeding preterm infant formula or non-study human milk fortifier * expected at facility less than 15 days * congenital anomalies/disease affecting growth and development * 5 minute apgar of 4 or less * steroid use * ecmo * grade iii or iv pvh/ivh * mechanical ventilator dependency * maternal incapacity * history of major surgery * asphyxia * confirmed nec or sepsis * use of probiotics
tpvb, pecsb, espb for postmastectmy pain

Conditions: Pain, Postoperative

Summary: aim of the work the aim of the study is to compare between the effects of ultrasound guided thoracic paravertebral block, pectoral nerve block ii, and erector spinae block in management of pain during cancer breast surgeries. the hypothesis of the study is that the three groups will give comparative results.


Eligibility criteria:
inclusion criteria: 1. asa physical status classification class i or ii 2. age group 18 - 60 years of the female gender 3. patients undergoing breast cancer surgeries exclusion criteria: 1. patient refusal 2. history of hypersensitivity to local anesthetics 3. bleeding disorders or patients receiving anticoagulants 4. spine or chest wall deformities 5. pregnancy 6. local infection at the site of injection.
vitamin d in vulnerable adults (viva-va)

Conditions: Frail Elderly; Vitamin d Deficiency

Summary: vitamin d insufficiency is a problem of growing concern, given its prevalence in older persons and the association of low vitamin d with multiple major health problems, including mobility and balance deterioration and falls, cardiovascular disease, diabetes, and certain cancers. sedentary persons are particularly vulnerable for these health problems and generally not adherent to prescribed physical activity. this study will investigate if treatment with vitamin d will benefit physical performance in male veterans age 65 to 95.


Eligibility criteria:
inclusion criteria: * male veterans * 65 to 95 years of age * independent * sedentary * vitamin d insufficiency exclusion criteria: * hypercalcemia * renal failure * living in a nursing home

Keywords: aged vitamin d deficiency
clinical and endoscopic pattern in children presented with upper and lower gastrointestinal bleeding insohag university hospital

Conditions: Upper and Lower Gastrointestinal Bleeding

Summary: gastrointestinal bleeding (gib) is one of the most common conditions in the emergency department. upper gib is a major problem that has been decreasing over the past 20 years but still has high mortality rate. gib usually manifests as hematemesis (vomiting of blood or coffee-ground-like material), melena (black or tarry stools), and hematochezia. ugib appears as hematemesis in 40%-50%, and as melena or hematochezia in 90%-98%,however, patients with lgib typically present with hematochezia, but right-sided colonic bleeding or small bowel bleeding may show as melena. endoscopy is the standard of care in the diagnosis and treatment of ugib. it helps to identify the source of bleeding, establish the underlying etiology ,achieve hemostasis and provide prognostic information to predict the risk of rebleeding causes of ugib are broadly divided into variceal and nonvariceal (peptic ulcer disease, reflux esophagitis, gastroduodenal erosions, tumors, vascular ectasia, etc. egd is the diagnostic modality of choice for ugib with more sophisticated investigations such as computed tomographic angiography and capsule endoscopy being rarely indicated where endoscopy is inconclusive .the primary diagnostic test for upper gi bleed workup is endoscopy. sensitivity of 92 % - 98 % and specificity of 30 % - 100 % is present for endoscopy for the diagnosis of upper gi bleed. severity scoring system like rockall's score, helps to identify the patients who are at higher risk for rebleed and mortality. lower gastrointestinal ( gi ) haemorrhage is defined as bleeding distal to the ligament of treitz. most of the pathological lesions and haemorrhage in the lower gi tract are usually located in the rectum , sigmoid and left sided colon.it is usually suspected when patients complain of haematochezia (passage of frank bright red blood) or bloody diarrhea.most of the bleeding from the lower gi tract stops spontaneously and patients usually have favorable outcomes compared to upper gi haemorrhage. however, morbidity and mortality tend to increase in older patients and with other pre existing co morbidities.


Eligibility criteria:
inclusion criteria: * children under 18years old who present with upper and lower gastrointestinal bleeding exclusion criteria: * bleeding due to systemic causes
sorafenib in first-line treatment of advanced b child hepatocellular carcinoma

Conditions: Advanced Adult Hepatocellular Carcinoma

Summary: the purpose of this study is to to compare the addition of sorafenib (800 mg/day)to best supportive care with best supportive care alone in terms of survival in patients with hepatocellular carcinoma (hcc) with impaired liver function (child b).

hepatocellular carcinoma (hcc) is the third cause of death for cancer in the world with an increasing incidence. no systemic therapy has proven effective in patients with advanced hcc until 2007, when results of the sharp trial were presented. in this trial, the orally active multi-kinase inhibitor sorafenib (800 mg/day) significantly prolonged survival compared with placebo in patients with advanced hcc and good liver function (child a). the same authors concluded that the effect of the drug in the population of patients with more impaired liver function should be further studied.

Eligibility criteria:
inclusion criteria: * patients with diagnosis of hepatic cell carcinoma (hcc) according to the aasld- easl criteria * age \>18 years * advanced stage of disease defined as hcc not eligible for locoregional treatments (ab initio or following progression after such treatments) * liver function classified as child-pugh class b * ecog performance status \< or = 2 * life expectancy of at least 2 months * adequate contraception for fertile male and female patients * signed informed consent exclusion criteria: * prior exposure to sorafenib or antiangiogenesis drugs * concomitant diseases that contraindicate the use of sorafenib * gastro-intestinal bleeding in the previous 30 days * altered renal function(creatinine \> 1.5 x uln), or haematological function (platelet count \< 60 x 10\^9/l, hemoglobin \< 9 g/dl) * serious active infections (\> grade 2 ctcae version 3.0) * congestive heart failure, history of congestive heart failure, unstable angina pectoris, myocardial infarct or significant valvular heart disease or uncontrolled heart arrhythmia * patients who are unable or unwilling to participate in the study * pregnant or lactating females * hepatic encephalopathy of any grade

Keywords: child pugh b first line
assessment of bone biomarkers for tki response in rcc with bone metastases, hrqol and comparison of imaging techniques

Conditions: Renal Cell Carcinoma

Summary: prospective observational study to assess bone predictive biomarkers for tki response in rcc patients with bone metastasis and hrqol with tki in these patients as well as the sensitivity and specificity of whole body magnetic resonance versus bone scintigraphy and versus ct in the assessment of metastatic lesions at bone level and at other sites.

prospective observational study to assess: * bone predictive biomarkers for tyrosine kinase inhibitor (tki) response in renal cell carcinoma (rcc) patients with bone metastasis - health related quality of life (hrqol) with tki * comparison of the sensitivity and specificity of whole body magnetic resonance versus bone scintigraphy and versus computerized tomography (ct) in the assessment of metastatic lesions at bone level and at other sites.

Eligibility criteria:
inclusion criteria: * diagnosis of a stage iv renal cell carcinoma with confirmed presence of bone metastases, subsidiary of treatment with an tki in first line * 18 years old or more * life expectancy \> 12 weeks * eastern cooperative oncology group performance status (ecog ps): 0 - 2 * capability of understanding the study and completing the numerical pain scale, diary of analgesics and quality of life forms * patient who has given informed consent * adequate renal, hepatic and hematologic functions exclusion criteria: * pregnancy, breastfeeding or fertile patients who do not use adequate contraceptive methods * non-clear cell histology * non irradiated brains metastases * symptomatic brain metastases * inability to undergo any of the medical tests of the study * a history of breast cancer or melanoma. other tumors are accepted as long as the patients has been for at least 5 years free of disease * synchronic diagnosis of another neoplasm * presence of an active infection * any decompensated disease or metabolic disorder * cardiac events or pulmonary embolism in the 12 months previous to inclusion

Keywords: metastatic, bone metastases